Parkinson's disease patients in SC take drugs to help ease symptoms but can often be left on a yo-yo of up and down time. A new drug pump helps smooth that out.

The drug is intended for patients experiencing “off” periods, where medication wears off and symptoms return or worsen. The approval is based on a Phase III, 12-week study (NCT02006121 ...

Researchers are using an advanced brain imaging method called MEG to understand why Parkinson’s drug levodopa doesn’t work ...

Parkinson’s drugs are meant to keep patients in what’s called their “on state,” providing improvement in coordination and stiffness. ... Before I got the new medication through the pump.

AbbVie has launched its Produodopa for Parkinson’s in the EU, becoming the first and only 24-hour levodopa-based subcutaneous infusion therapy for the disease.

Three strikes and you’re out? Not for Supernus Pharmaceuticals and its Parkinson’s disease infusion pump. On its fourth attempt to pass muster with the FDA, the company’s SPN-830, now ...

The drug is administered via a pump worn around the midriff, which measures 8in x 3in (200mm x 75mm) and weighs 307 grams. A fine tube connects the pump to a cannula that has to be changed daily.

Medical Watch Digest for August 8 A powerful drug to treat Parkinson’s The disease causes muscle rigidity and spasms making everyday tasks nearly impossible. But when a 52-year-old United ...

Supernus Pharmaceuticals has won US approval for its wearable pump Onapgo (apomorphine hydrochloride) to treat symptoms of Parkinson’s disease. Supernus’ regulatory path for Onapgo has been ...

The drug is administered via a pump worn around the midriff, which measures 8in x 3in (200mm x 75mm) and weighs 307 grams. A fine tube connects the pump to a cannula that has to be changed daily.

Supernus Pharmaceuticals has won US approval for its wearable pump Onapgo (apomorphine hydrochloride) to treat symptoms of Parkinson’s disease. Supernus’ regulatory path for Onapgo has been ...